Oncotarget

Research Papers:

Identification of novel small molecule inhibitors of centrosome clustering in cancer cells

Eiko Kawamura, Andrew B. Fielding, Nagarajan Kannan, Aruna Balgi, Connie J. Eaves, Michel Roberge and Shoukat Dedhar _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2013; 4:1763-1776. https://doi.org/10.18632/oncotarget.1198

Metrics: PDF 2333 views  |   HTML 2123 views  |   ?  


Abstract

Eiko Kawamura1, Andrew B. Fielding1,2, Nagarajan Kannan3, Aruna Balgi4, Connie J. Eaves3,5, Michel Roberge4, Shoukat Dedhar1,4

1 Department of Integrative Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

2 current address: Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

3 Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada

4 Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada

5 Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada

Correspondence:

Shoukat Dedhar, email:

Keywords: Centrosome Clustering, multipolar mitosis, small molecule, cancer specific, spindle

Received: September 10, 2013 Accepted: September 23, 2013 Published: September 25, 2013

Abstract

Most normal cells have two centrosomes that form bipolar spindles during mitosis, while cancer cells often contain more than two, or “supernumerary” centrosomes. Such cancer cells achieve bipolar division by clustering their centrosomes into two functional poles, and inhibiting this process then leads to cancer-specific cell death. A major problem with clinically used anti-mitotic drugs, such as paclitaxel, is their toxicity in normal cells. To discover new compounds with greater specificity for cancer cells, we established a high-content screen for agents that block centrosome clustering in BT-549 cells, a breast cancer cell line that harbors supernumerary centrosomes. Using this screen, we identified 14 compounds that inhibit centrosome clustering and induce mitotic arrest. Some of these compounds were structurally similar, suggesting a common structural motif important for preventing centrosome clustering. We next compared the effects of these compounds on the growth of several breast and other cancer cell lines, an immortalized normal human mammary epithelial cell line, and progenitor-enriched primary normal human mammary epithelial cells. From these comparisons, we found some compounds that kill breast cancer cells, but not their normal epithelial counterparts, suggesting their potential for targeted therapy. One of these compounds, N2-(3-pyridylmethyl)-5-nitro-2-furamide (Centrosome Clustering Chemical Inhibitor-01, CCCI-01), that showed the greatest differential response in this screen was confirmed to have selective effects on cancer as compared to normal breast progenitors using more precise apoptosis induction and clonogenic growth endpoints. The concentration of CCCI-01 that killed cancer cells in the clonogenic assay spared normal human bone marrow hematopoietic progenitors in the colony-forming cell assay, indicating a potential therapeutic window for CCCI-01, whose selectivity might be further improved by optimizing the compound. Immunofluorescence analysis showed that treatment with CCCI-01 lead to multipolar spindles in BT-549, while maintaining bipolar spindles in the normal primary human mammary epithelial cells. Since centrosome clustering is a complex process involving multiple pathways, the 14 compounds identified in this study provide a potentially novel means to developing non-cross-resistant anti-cancer drugs that block centrosome clustering.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1198